Cargando…
Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
Approximately 20%–25% of all breast cancers over express a key cell surface growth factor receptor known as HER2. HER2 plays a key role in cell growth and proliferation and is linked to worse clinical outcomes, making it a logical therapeutic target. The first HER2 targeted drug to be approved by th...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306225/ https://www.ncbi.nlm.nih.gov/pubmed/22438669 http://dx.doi.org/10.4137/BCBCR.S6374 |